Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2023HeliyonOpen Access

Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNabarun MukhopadhyayNational Institute of Pharmaceutical Education and ResearchASAshtabhuja ShuklaNational Institute of Pharmaceutical Education and ResearchPMPriyanka N. MakhalInstitute for Stem Cell Biology and Regenerative Medicine

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mukhopadhyay et al. (2023) studied this question.

synapsesocial.com/papers/69fd2de6015782f43c509e92https://doi.org/10.1016/j.heliyon.2023.e14569
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein2006 · 41 citations
  2. 2Novel quinazoline and acetamide derivatives as safe anti-ulcerogenic agent and anti-ulcerative colitis activity2017 · 12 citations
  3. 3Leukotrienes: Underappreciated Mediators of Innate Immune Responses2005 · 330 citations
  4. 4Pathophysiological Perspective of Osteoarthritis2020 · 199 citations
  5. 5Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs.2000 · 150 citations